PranaX is a Houston-based regenerative medicine biotechnology company developing stem cell-derived exosome products to counter aging, inflammation, and tissue damage. Built on exosome technology exclusively licensed from The University of Texas MD Anderson Cancer Center, PranaX operates an FDA-registered cGMP facility at the Levit Green life science campus and is bringing to market a physician-directed exosome wellness supplement (ExoWELL) and a personal exosome banking service (ExoSTORE). The company closed an oversubscribed $17M Series A in early 2026.
Epirium Bio is a San Diego-based clinical-stage biopharmaceutical company developing orally available small molecules that target PGE2 signaling to restore tissue homeostasis, reduce inflammation, and stimulate regeneration. Its lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor advancing toward a Phase 2b trial for sarcopenia, the age-related loss of muscle strength for which no FDA-approved therapy currently exists.